Anatara Lifesciences is developing evidence based solutions for gastrointestinal diseases in humans and animals.
Introducing Anatara’s technology
GaRP is the working name for Anatara’s evidence based complementary medicines using unique formulations of bromelain, an enzyme extracted from pineapple stems along with other synergistic GRAS components. The combination and coating of these GaRP components have a beneficial effect on the physiology of the gastrointestinal lining, a positive influence on the microbiome (homeostasis & metabolites) and allows absorption of components in targeted areas of the gastrointestinal tract. GaRP’s multimodal activity provides a versatility for tailoring the components to various indications and we presently have in progress two human trials.
Anatara is developing proprietary formulations for gastrointestinal health.
Introducing Gastrointestinal ReProgramming (GaRP), a microbiome-targeted complementary medicine
Anatara’s GaRP product is a microbiome-targeted multi-component complementary medicine that has been designed to address the primary underlying factors associated with gastrointestinal disorders such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).
A new formulation, 3FDC, was developed using GaRP technology. 3FDC has been designed with 3 components with functional delivery coatings which are released in the large intestine (colon) to positively influence the gut-brain connection, targeting modulation of psychobiological processes driving anxiety-related disorders and to assist homeostasis of the “gut” to promote overall health and wellbeing.
Our pipeline products are being positioned as adjuncts to existing therapies, and will not be replacing current prescription medications. Over the last 20 years the use of complementary medicine as adjuncts to prescription drugs has increased significantly.
Our Human Applications page provides further information on our human development plans.
Anatara’s team and opportunity
Backed by a well credentialed Board and Management team, and world-leading scientific collaborators, Anatara is uniquely positioned to fulfill a significant unmet medical need in gut health in humans.
Anatara’s lead product, Detach®, is a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour).
Scour in piglets is an expensive, debilitating and in some cases, life-threatening condition. Increasing survivability and providing health benefits to pre-weaning piglets has been at the core of the development of Detach® since the Company was listed in 2014.
In October 2018, Anatara announced that the Australian Pesticides and Veterinary Medicines Authority (APVMA) had registered Detach® with the approved label, “To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets”.
Anatara is evaluating commercialisation opportunities for Detach® including options for launch of the APVMA approved product in Australia, regulatory approval of this product in overseas markets, development of this product for species other than piglets and, global or regional licensing of Detach®.
Our Animal Applications page provides further information on our Detach® development plans.